Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 57 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

18%

9 of 50 completed trials have results

Key Signals

3 recruiting9 with results

Enrollment Performance

Analytics

Phase 1
55(96.5%)
N/A
1(1.8%)
Early Phase 1
1(1.8%)
57Total
Phase 1(55)
N/A(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (57)

Showing 20 of 57 trials
NCT07518459Phase 1Completed

A Study of Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]AZD4144

Role: collaborator

NCT07011511Phase 1Recruiting

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants

Role: collaborator

NCT05051566Phase 1Completed

A Multiple Dose Study of LY3502970 in Healthy Participants

Role: collaborator

NCT06500793Phase 1Recruiting

Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

Role: collaborator

NCT07220954Phase 1Recruiting

A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234

Role: collaborator

NCT06558643Phase 1Completed

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants

Role: collaborator

NCT07453784Phase 1Not Yet Recruiting

Phase 1 Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation

Role: collaborator

NCT06144684Phase 1Completed

A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295

Role: collaborator

NCT05294458Phase 1Completed

A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects

Role: collaborator

NCT06989983Phase 1Completed

A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462

Role: collaborator

NCT05817461Phase 1Completed

An ADME Study of [14C]AZD0780 in Healthy Male Subjects

Role: collaborator

NCT06857695Phase 1Completed

A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004

Role: collaborator

NCT05413668Phase 1Completed

First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent

Role: collaborator

NCT05507970Phase 1Completed

First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367

Role: collaborator

NCT06543043Phase 1Completed

A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers

Role: collaborator

NCT05090280Phase 1Completed

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)

Role: collaborator

NCT05364255Phase 1Completed

A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

Role: collaborator

NCT06157255Phase 1Completed

An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604

Role: collaborator

NCT05012670Phase 1Completed

Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects

Role: collaborator

NCT03437265Phase 1Completed

A Pharmacokinetic Study of PLENVU® in Healthy Subjects

Role: collaborator